BridgeMD
New treatment option for Hepatocellular Carcinoma
Official title Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
ClinicalTrials.gov ID: NCT06446154
What this study is testing
What is Fruquintinib?
Fruquintinib is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for hepatocellular carcinoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Nowadays, there are few second-line treatment options for advanced hepatocellular carcinoma (HCC). In order to further improve the efficacy of second-line treatment for advanced HCC, we plan to conduct a phase II clinical study to explore the efficacy and safety of the new second-line treatment for advanced HCC.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- patients aged 18 years or older
- with unresectable, locally advanced, or metastatic HCC, with the diagnosis confirmed by histologic or cytologic analysis or clinical features...
- who had previously received immune checkpoint inhibitors
- had at least on measurable disease, as defined by Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST v1.1) criteria
- had a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
You likely can't join if
- history of HIV, organ allograft
- combined with other malignant tumors
- evidence of hepatic decompensation, bleeding diathesis or event
- allergy to the investigational agents or any agent given in association with this trial
- incomplete medical information.
See the full eligibility criteria
- patients aged 18 years or older
- with unresectable, locally advanced, or metastatic HCC, with the diagnosis confirmed by histologic or cytologic analysis or clinical features according to the American Association for the Study of Liver Disease criteria
- who had previously received immune checkpoint inhibitors
- had at least on measurable disease, as defined by Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST v1.1) criteria
- had a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- had a Child-Pugh liver function score of 7 or less
- had adequate hematologic and organ function (absolute neutrophil count ≥1.2×109/l, platelet count ≥60×109/l, total bilirubin \< 30μmol/l, albumin ≥ 30g/l, aspartate transaminase and alanine transaminase ≤ 5×upper limit...
- history of HIV, organ allograft
- combined with other malignant tumors
- evidence of hepatic decompensation, bleeding diathesis or event
- allergy to the investigational agents or any agent given in association with this trial
- incomplete medical information.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.